Shop All
Non-alcoholic fatty liver disease now affects 25% of the global population, driven by the insulin resistance-hepatic lipid accumulation cascade. Explore how fucoidan inhibits hepatic stellate cell activation to reduce fibrosis markers (documented in animal models), how the gut-liver axis connects sea moss prebiotic fiber to reduced endotoxin translocation and hepatic inflammation, and how B vitamins support methylation and SAMe production critical for liver detoxification Phase II. Critical: sea moss cannot treat cirrhosis, hepatitis, or established NASH -- hepatologist evaluation required.
For the complete science-backed breakdown, including mechanisms, dosing, timing, and safety considerations, read our full guide:
Sea Moss for Liver Health: Fucoidan Hepatoprotection, Gut-Liver Axis, and NAFLD Support
Key topics covered:
- The specific compounds in sea moss relevant to this condition
- Mechanistic pathways (not just anecdotal claims)
- Evidence-based dosing protocols and timing
- Drug interactions and contraindications
- How to integrate with conventional medical care
- What results are realistic and on what timeline
